Q1 FY27 results: Revenue up 336% YoY, PAT jumps about 14 times

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+7.5%Reaction day

₹37.00

prior close

₹37.25

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%+7.1% vs market

Pharmaceuticals peers, median of 166sector-0.6%+8.1% vs sector

On the reaction day the stock moved 7.1 pts more than Nifty Microcap 250 and 8.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+7.8

10m

+6.9

15m

+7.0

30m

+6.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+7.5+0.4+7.1-0.6+8.1

Next day

+11.5+0.5+11.0-0.3+11.8

—+0.6—-0.6—

—+0.7—-1.4—

—+1.1—-1.1—

—+0.5—-1.9—

—+1.3—-1.4—

15d

—+0.5—-1.0—

—-0.8—-0.2—

—-0.9—-3.2—

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shukra Pharmaceuticals Q1 FY27 standalone revenue from operations surged to Rs 2,352.23 lakhs from Rs 539.11 lakhs a year ago. Net profit jumped to Rs 1,502.98 lakhs from Rs 102.96 lakhs. EPS stood at Rs 0.34 versus Rs 0.02. Consolidated PAT was Rs 1,295.85 lakhs. Shah Sanghvi and Associates issued an unmodified review report. No investor complaints pending. Company operates in Pharmaceutical and MedTech segments.

Likely market impact

Sharp topline and bottomline growth signals strong operational turnaround, positive for shareholders.